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Abstract 
The information and communication technologies (ICTs) field is expanding rapidly and 
affecting several domains of mankind, as for example healthcare. Therefore, ICTs can act as 
an enabler or a provider these fields through telemedicine. Consequently, promoting an 
human centred and ethical approach is the primary challenge concerning ICT healthcare 
innovation. Simultaneously, can we deter- or at least discourage- innovation that serves 
malicious ends, or that causes serious threats to humanity? 
So, the purpose of this contribution is to discuss the relationship between ICT evolution and 
healthcare, particularly concerning a specific correlated research fields: bionanotechnology 
and telemedicine. For that, we will focus in its applications, and sort of ethical and moral 
dilemmas encompasses. 
 
Introduction 
Innovation by tradition was viewed as a linear process: from basic research to technology 
progress, test/evaluation, demonstration, deployment, commercialization, and ultimately, 
market penetration. And possibly, if successful, market saturation, obsolescence, and finally 
substitution. Human (and social) factors- needs, desires, demands, behaviour- were 
considered either not intuitively, anecdotally, coincidentally, mechanically, and often 
reactively. Innovation was firstly defined as hard science, engineering, and production, with 
marketing and sales trailing behind, as “army camp followers”. Therefore, the primary 
challenge to promulgate a more human centred and ethical approach to manage and account 
for innovation is: 
• can we encourage innovation that adds net social value? That is, whose benefits 
clearly outweigh its costs? 
• at the same time, can we deter- or at least not encourage- innovation that serves 
malicious ends or that causes serious threats to humanity? 
 
Plus, it seems obvious that healthcare innovation have huge benefits from ICT; however, such 
technologies have the ability to affect positively and negatively patients, and so society must 
investigate their impacts, namely in telemedicine. Nevertheless, the main purpose is to 
approach bionanotechnology as a research field. But, how can we define bionanotechnology? 
As we will demonstrate, such concept is still an ongoing debate, and for that we need to 
address two levels of arguing: 
• what is biotechnology? Which are its applications, particularly medical applications? 
What ethical and moral dilemmas arise? 
• what is nanotechnology? Which are its applications, particularly medical? What 
ethical and moral dilemmas occur? 
 
Biotechnology can be broadly defined as the condition of using organisms or their products 
for commercial purposes. It has been used into food, crops or domestic animals; but, recent 
developments in molecular biology have given biotechnology a new meaning, prominence, 
and potential. It is (modern) biotechnology that has captured the attention of the public, and of 
course encompasses a great deal of ethical and moral dilemmas. 
Nanotechnology is the creation of functional materials, devices, and systems through control 
of matter on the nanometer length scale, the exploitation of novel properties and phenomena 
developed at that scale (Bonsor, 2002). Throughout literature it is possible to find several 
examples of nanotechnology applications: giant magnetoresistance in nanocrystalline 
materials, nanolayers with selective optical barriers, nanomedicine robots, etc. (Institute of 
Molecular Manufacturing, 2003). Concerning the possible and moral dilemmas of such 
technology it is usual that philosophers, ethicists and many scientists frequently speak as if 
such objects will exist in a nearly future, but in fact they already exist which clearly creates a 
policy vacuum (Moor, 2001). 
Only after such discussion is feasible to acknowledge the aim of your contribution: how can 
we define bionanotechnology as a research field? Which are its medical applications? What 
sort of ethical and moral dilemmas are involved? And, could the level of such dilemmas be a 
sum of biotechnology and nanotechnology, or imposes new challenges? 
 
Background 
E-health versus telemedicine 
ICT have been developing rapidly for several decades now. Thus, the health sector has 
witnessed the creation of a vast number of applications: 
• telemedicine, which is leading to a radical change in medical practices and in 
practitioner/patient relationship; 
• e-health, which provides sources of information and new services for practitioners and 
patients; 
• smart cards, which allow claim forms to be sent electronically and may, in the middle 
term, be used for other services and procedures. 
 
Accordingly, previously to our stream analysis we need to debate some important features: 
understanding why such health technologies are so innovative? And, what characterizes 
telemedicine and e-health? New health technologies not only disorder relationships we have 
with other people, they in addition redefine our connection towards our own body and our 
sense of being healthy or sick, our sense of control over our body and its parts. As Webster 
(2007) argues, such technologies possess the ability to reinvent the boundaries of our body in 
space and time by tumbling them to their basic level of biological assembly, embracing 
therefore a great deal of ethical dilemmas. 
The terms telemedicine and e-health are sometimes confused or broadly used interchangeably, 
however what is the correct word? How the mass in terminology has emerged? Initially the 
word “telemedicine” was commonly used, however today we have moved forward… 
The term telemedicine is a combination of two words (the Greek τήλε equal to tele, which 
means “at a distance”; and, ars medicina meaning “healing”). Telemedicine can be defined as 
a delivery of healthcare and exchange of health care information across distance (Wootton, 
Craig & Patterson, 1999). Or, the World Health Organization defines it as “the delivery of 
healthcare services, where distance is a critical factor, by all healthcare professionals using 
information and communications technologies for the exchange of valid information for 
diagnosis, treatment and prevention of diseases and injuries, research and evaluation, and for 
the continuing education of healthcare providers, all in the interests of advancing the health of 
individuals and their communities” (World Health Organization, 2005, pp. 1). Given such 
definitions we may claim that telemedicine can be divided into three areas: aids to decision-
making, remote sensing, and collaborative arrangements for the real-time management of 
patients at a distance. However, some have suggested that telemedicine is not a technology 
per se but rather a technique that delivers care remotely (Loane & Wootton, 2002). Even so, 
the need for moral endeavour must be a reality. 
Contrarily, the term e-health is considered a neologism. So, e-health is “today’s tool for 
substantial productivity gains, while providing tomorrow’s instrument for restructured, 
citizen-centred healthcare systems and, at the same time, respecting the diversity of Europe’s 
multi-cultural, multi-lingual healthcare traditions. There are many examples of successful e-
health developments including health information networks, electronic health records, 
telemedicine services, wearable and portable monitoring systems, and health portals” 
(Comission of the European Communities, 2004, pp. 4). Gustafson & Wyatt (2004) define it 
as patients and the community using the internet or other electronic media to propagate or 
supply access to health and lifestyle information or services. This differs from telemedicine, 
in which there is a health professional at one or both ends of the communication. 
So, Eysenbach (2001) into the 20th editorial concerning Journal of Medical Internet Research 
acknowledges the following major characteristics for e-health: 
• efficiency- one of the promises of e-health is to enhance effectiveness in health care, 
therefore diminishing costs; 
• enhancing quality of care- the previous feature involves not only sinking costs, but 
simultaneously improving quality; 
• evidence based- e-health involvements should be evidence-based in a sense that their 
efficacy and efficiency should not be taken accepted as granted, but confirmed by 
rigorous scientific assessment; 
• empowerment of consumers and patients- knowledge bases of medicine and personal 
electronic records accessible to consumers, allows a patient-centred medicine, and 
facilitates evidence-based patient choice; 
• encouragement of a new relationship between the patient and health professional; 
• education of physicians through online sources (continuing medical education) and 
consumers (health education, tailored preventive information for consumers); 
• enabling information exchange and communication in a standardized way between 
health care institutions; 
• extending the range of health care beyond its conventional boundaries; 
• ethics- these new forms of patient-physician interaction poses new challenges and 
threats to ethical issues; 
• equity- in spite of being one of the promises concerning e-health, the truth is that the 
digital divide may enhance the gap between the “haves” and “have-nots”. 
 
However, Wyatt & Sullivan (2007) question e-health promises pointing out some pressures 
that the use of e-health comprise: 
• patient demand- information and services can be delivered in a personalised way, 
where and when wanted or needed; 
• new functions- it can link previously distinct services and information; 
• democracy- it could let society form pressure groups, lobby for services, or even set up 
their own health organizations; 
• health workforce- it may help with staff shortages or requests from staff for improved 
working lives; 
• technology- futuristic devices will become more reliable, functional and cheaper; 
• national policy- towards services will have an easier coordination, promoting equity 
and patient independence, adhering to government targets and lowing carbon dioxide 
emissions; 
• economics- may shift some costs to the patient or into the community; 
• safety- it will possibly improve personal management and avoidance of exposure to 
methicillin resistant Staphylococcus aureus. 
 
In conclusion, e-health encompasses the need for applied ethics as suggested by Collste 
(2008), as well as, cross-cultural issues are a reality (see Stahl, Rogerson & Kashmeery, 
2006). 
 
Biotechnology and its applications 
Contrary to it is name, biotechnology is not a single technology. Rather it is a group of 
technologies that share two common characteristics: working with living cells and their 
molecules; and, having a wide range of practice uses that can improve our lives. In spite of 
such claim, we will plead that biotechnology is unique amongst the three major technologies 
for the twenty-first century- information technology, materials science, and biotechnology- in 
being a sustainable technology based on renewable biological resources. Such natural 
resources include animals, plants, yeasts, and microorganisms and have formed mankind’s 
nascent food and beverage industry for several millennia. 
So, biotechnology can be broadly defined as “using organisms or their products for 
commercial purposes” (National Agricultural Library, 2008). But recent developments in 
molecular biology have given to biotechnology a new meaning, prominence, and potential. It 
is (modern) biotechnology that has captured the attention of the public, which has a dramatic 
effect on the world economy and society. 
Historically, the modern era of scientific biotechnology begins with the elucidation of the 
DNA structure by Watson and Crick in 1953, and the subsequent development of the tools to 
cleave and resplice genetic material in the early 1970s. Not surprisingly, therefore, the term 
biotechnology is generally considered synonymous with gene splicing and other forms of 
genetic engineering. 
However, in the future, the most significant breakthroughs in human medicine will result 
from mapping and understanding the human genome. With less than five per cent of all 
human genes identified, it has become increasingly clear that each new gene discovery 
proffers new drugs for the diagnosis, treatment, and prevention of human disease. These 
advances will enable biotechnologists not only to measure disease potential and expand the 
applications for genomic diagnostics, but also to devise fundamental new therapeutic 
approaches. Products and medical applications of modern biotechnology include: 
• artificial blood vessels- from collagen tubes coated with a layer of the anticoagulant 
heparin (Huynh et al., 1999); 
• gene therapy (altering DNA within cells in an organism to treat or cure a disease)- in 
order to develop therapies to treat diseases such as cystic fibrosis, AIDS and cancer 
(Biotechnology Industry Organization, 2008); 
• genetic code tests- to understand, treat or prevent patient's diseases (examples are: 
carrier tests to identify genetic abnormalities that do not affect the person being tested, 
diagnostic tests make or confirm a diagnosis where symptoms or other indications are 
present, preimplantation tests can be conducted on embryos before they are transferred 
to the uterus in in vitro (IVF) fertilisation programs, and prenatal tests) (Verlinsky & 
Kuliev, 2004); 
• xenotransplantation- involves the transplantation of organs, tissues, or cells from one 
species to another (Cooper, 1996). Of course, the aim about transplantation from 
animals into humans, is to fulfil the demand for transplantable organs, tissues and cells 
to alleviate disease and save human lives; 
• human biobanks and genetic research databases- “structured resources that can be used 
for the purpose of genetic research, which include: a) human biological materials 
and/or information generated from the analysis of the same; and b) extensive 
associated information” (Organization for Economic Co-operation and Development, 
2008, pp. 5). 
 
Genomics and genetic engineering are also playing a substantial role in the development of 
agricultural biotechnology. The early goals in the development of transgenic livestock were 
the increase of the meat and of the production characteristics of food animals. However, long 
research and development timelines and low projected profit margins, especially in developed 
nations where food is relatively inexpensive; have shifted priorities to the production of 
protein pharmaceuticals and nutraceuticals in the milk of transgenic animals (Lowe, 1999). 
Plus, marine organisms are also capable of producing a variety of polymers, adhesives, and 
compounds for cosmetics and food preparation. Bioactive natural products are found in 
organisms that reside in areas which stretch from easily accessible intertidal zones to depths 
in excess of 1000 meters. Collaborations between marine chemists, molecular 
pharmacologists, and cell biologists have yielded an impressive library of potentially use 
(National Agricultural Library, 2008). However there are so many catalysts still to be 
discovered, which will have to exhibit improved performance, stability, turnover numbers, 
specificity, and product yields. 
Biotechnology is also playing a role in clean manufacturing. Nevertheless, various types of 
chemical manufacturing, metal plating, wood preserving, and petroleum refining industries 
currently generate hazardous wastes, comprising volatile organics, chlorinated and petroleum 
hydrocarbons, solvents, and heavy metals. Bioremediation with microbial consortia is being 
investigated as a means of cleaning up hazardous sites. Methods include in situ and ex situ 
treatment of contaminated soil, groundwater, industrial wastewater, sludges, soil slurries, 
marine oil spills, and vapour-phase effluvia. 
Finally, biotechnology is being currently used in DNA fingerprinting (process of cross 
matching two strands of DNA) namely into the following fields (Biotechnology Industry 
Organization, 2008): 
• criminal investigations- DNA from samples of hair, body fluids or skin at a crime 
scene as a way to confirm suspects is enhancing rapidly; 
• polymerase chain reaction (PCR)- process that entails into a more quick and accurate 
way of identify the presence of infections such as AIDS, Lyme disease and 
Chlamydia; 
• paternity determination (another genetic test)- through DNA it is possible to confirm if 
a child’s DNA pattern is inherited, half from the mother and half from the father; 
• human fossils- to determine how closely related fossil samples are from different 
geographic locations and geologic areas. The results shed light on the history of 
human evolution and the manner in which human ancestors settled different parts of 
the world. 
 
The ethical dimensions of biotechnology 
The ethical issues created by biotechnology are vast and growing. Our present moral systems 
work mightily to reconcile the new world order into their established patterns of accepted 
behaviour. The ethics of biotechnology raises immensely complex issues; the biotechnology 
of ethics raises even more intractable ones. Our current scientific advances allow us to 
engineer the most basic of our life processes: 
• the dissemination in our environment of genetically modified organisms (GMO); 
• the genetic modifications and their use in food; 
• the applications of research in human genetics. 
 
The publication of the first experimental protocols as a technique for genetic engineering 
occurred in 1973 (on micro-organisms) raised the fear into researchers: many biologists 
considered it was a high risk activity, and therefore restrictive measures were taken. The 
GMOs had to be confined and prevented from disseminating in the environment. They could 
modify the “balance of nature” and subsequently the foreign DNA could change the 
metabolic activity in an unpredictable and undesirable way, producing unsuspected and 
irreparable damage to environment and mankind. In fact, science fiction literature was already 
starting the debate by presetting GMOs with the ability to destroy the reserve of raw 
materials, enhancing the lack of confidence concerning such organisms. 
With new progress in scientific knowledge and experimental techniques, it occurred to 
scientists not to confine the GMOs in bioreactors, but to let these organisms grow freely in the 
soil in order to improve: 
• the environment through micro-organisms with the ability to clean chemically 
contaminated soils (bioremediation); 
• and, the performance of vegetal culture. 
 
However, such decisions entail into a discussion regarding the relationships between these 
GMOs and other organisms (including human beings). Won’t the modified characteristics be 
transferred to other organisms, creating non intentional and, may be, damageable effects 
(Organization for Economic Co-operation and Development, 2005)? Our knowledge about 
the interactions between the microbial populations in an ecosystem is fragmentary, especially 
on the exchange of genetic material, but precise studies are going on (Biotechnology Industry 
Organization, 2005). No negative effects of the release of GMOs (micro-organisms) have 
been reported until now; however studies are being conducted (Biotechnology Industry 
Organization, 2005). The problem is to know if they can be set up with objectivity. The 
question remains open: can this problem be treated with objectivity, similar to debate 
regarding nuclear power? 
Biotechnology may soon provide us with the ultimate ability to “design” our individual moral 
senses and biologically “grow” implanted ethical codes of behaviour within the human being. 
The more commanding focus will be on the genetics of ethics, rather than on the ethics of 
genetics, as Backus, Spinello & Tavani (2004) demonstrate into one of the editorials of Ethics 
and Information Technology Journal, in which they introduce several papers concerning new 
challenging perspectives of this matter. 
Therefore, we need to recognize the extraordinary uniqueness of current life forms and how 
highly special and precious they remain. To the extent, modern science threatens the delicate 
symbiosis between our ethical and legal norms and our biological evolution. New, daily 
scientific advances leave a moral order ill-equipped to respond. Ethical choices are the result 
of deeply ingrained predispositions and a lifetime of cultural adaptation. When faced with 
new situations, we tend to respond slowly, viewing any significant departure from the moral 
status quo as a threat. The law also inherently moves slowly, proceeding through careful 
analysis and studied reflection. Legal precedent and a hierarchical judicial system lend 
additional brakes to an already sluggish, orthodox order. 
With such intrinsic conservatism, it should come as no surprise that we are today still 
strunggling, both ethically and legally, with technological breakthroughs that are decades old. 
Contraception and abortion are, at their core, denials of our biological selves (Thiele, 1999) 
and, thus we continue to be uncomfortable with the ramifications inherent in the utilization of 
the technology. Contraception is still vigorously debated in many societies, through 
technology that is now antiquated. 
Currently, biotechnology among many other things is enabling us to begin prenatal testing for 
fetal genetic conditions and to begin artificial manipulation of an unborn’s genotype. The 
intractable social, moral, and legal issues posed by only these two technological advances 
illustrate the potential impact of biotechnology in our society (Kevles & Hood, 1993). When 
is such testing viable and to whom should it be made available? Which genetic disorders or 
diseases will allow (require?) state regulated abortions or invasive procedures? Which are the 
rights of a “good-gene” child to be weighed against maternal health and reproductive 
freedom? Who should bear the economic costs of raising a child conceived with certain 
knowledge of the genotype-disorder? Is there a duty for individuals to test in vitro so they 
may reject embryos that pose significant health costs over the embryo’s lifetime? What is a 
“bad” gene trait and how do we decide which embryos are “good” (Burgess, 2001)? What 
will happen at an ethnical level: will nations be characterized by homogeneous ethnic groups, 
encompassing therefore synonymous cultures (Brunger & Bassett, 1998), or biological 
diversity will still be a reality (Lujan & Moreno, 1997)? Will equity prevail (Farrely, 2004)? 
Another concern is the short shrift paid to concerns about biopiracy in isolated communities 
(Burgess, 2001). 
Moreover, all these dilemmas entail into an important discussion regarding biotechnology 
patents: it is possible for a company or a country to own our genetic evolution, instead 
mankind itself? In fact, there is a substantial debate in public forums and academic circles 
about whether patenting is morally and ethically acceptable (see for example: Gold, 2000; 
Lever, 2001; Witke, 2005). Regarding such matter, we claim the absence of patents regarding 
the human genome, but also through the example given by Collste (2008) concerning the HIV 
patentability. Plus, allowing patents over human genetic material will create a demand for 
such biological materials and will increase, the likelihood that individuals will be exploited 
(Einsiedel & Sheremeta, 2005), and also could actually inhibit research (Earnscliffe Research 
and Communications, 2005). 
Regarding the possible ethical issues related to potential human recipients of xenotransplants 
once again a considerable number arise: the potential subject, a patient with end-stage organ 
failure, is entitled to the same rights, respect, autonomy, and voluntary informed consent that 
are necessary for all human subjects (Barker & Polcrack, 2001). However, it will be difficult 
to guarantee that xenotransplatation first patients will be truly informed given the uncertain 
risk analysis (Clark, 1999). There may be risks that are not yet known and which, therefore, 
are unable to be quantified. 
Moreover, when the intention is to discuss biobanks we should pay attention to the following 
assumptions: 
• in identified biobanks, information is stored with samples including identifiers such as 
patient name or number; 
• in identifiable biobanks, unidentified samples can be linked back to identifiers through 
a coding system; 
• in anonymized biobanks, samples are irreversibly stripped of all identifiers and cannot 
be re-linked with those identifiers; 
• in anonymous biobanks, samples are collected without identifiers, therefore the source 
is impossible to identify. 
 
Plus, it seems clear that the purpose of the research and the source of the genetic material 
affects the nature of the identification used in a given research project. In fact, The Public and 
Professional Policy Committee of the European Society of Human Genetics (PPPC) 
recommends: different approaches to ownership of samples based on the character of the 
collection (Ayme, 2003), and that the various approaches to ownership should be subjected to 
multiparty contracts rather than defined in legislation. 
So, in spite of the possible differences concerning technical design it is possible to 
acknowledge the following common features: 
• biological source material- DNA can be extracted from very small amounts of human 
tissue; 
• genetic information systems- DNA is extracted from individual’s biological material 
and information describing the unique characteristics of the person’s genotype is 
stored in an electronic database; 
• phenotypic information- information derived through physical examination, from 
questionnaires, or from individual’s health records. 
 
Given such characteristics, the World Health Organization (2003) strongly recommends the 
existence of a security culture concerning health data protection. Still, Gostin (2001) claims a 
gigantic tension between personal privacy and public good regarding such information, which 
will be the key future challenge for biobanks (Norwegian University of Science and 
Technology, 2004), being information consent a fundamental value. 
Furthermore, genetic information consent is often perceived similar to general consent for 
research applications (Kerr, 2003); however, is well beyond those. Despite informed consent 
could be reduced to a simple signature, we follow McDonald (2000, pp. 304-305) that claim: 
“consent is a process of willing and knowing participation over time”, and in biobanks due to 
the sensitivity of the information they hold and the potentially lengthy time that they might 
hold it, we may claim that information consent is a “core value”: 
• re-consenting- explicitly rejects the presumption that it is possible to authorize future 
research, stating that informed consent is only valid if participants understand the 
specific nature, risks and benefits of this particular research; 
• blanket consent- the challenge presented by future research to informed consent can be 
described to research participants who can then decide whether or not to authorize that 
research. 
 
Clearly, all the previous questions remind us the importance of undertaking a critical 
reflection concerning the role of industry into biotechnology, as Rahul Dhanda (2002) in his 
book, “Guiding Icarus: Merging Bioethics with Corporate Interests” explores. Dhanda makes 
it clear at the outset that he is an industry insider, working for Interleukin Genetics. Therefore, 
he is not naive about the many pitfalls of industry or the social responsibility that it bears. 
Even if somenone disagree, as we do, Dhanda's position is very interesting concerning the 
following issues: 
• the critical importance of comprehensive informed consent procedures- such 
procedures are not only hints at the real problems with how informed consent is used 
(as a paper to sign rather than as an ongoing process), which undermines its protective 
utility; 
• the insufficient attention to whether DNA donors- such people are likely to understand 
what they are consenting to; 
• the DNA databases- as it occurs in any database, DNA databases can also produce 
errors and be violated, which means a blind faith in them will lead people to discount 
the possibility that their personal DNA information can be wrong; 
• the DNA patents- it should not be allowed to any company to patent the human 
genome, in spite of the valid economical argument concerning the costs of research. 
 
He is still convincing about the need to integrate bioethics as a corporate value within the 
biotechnology industry. However, such process is drastically difficult as the survey regarding 
ethical practices of bioscience companies suggest (see Finegold & Moser, 2006). Therefore, 
the need to hire human resources with high ethical standards should be a priority, but for that 
is imperative that educational systems for bioengineers include the teaching of ethics as Frize 
(2007) advocates. To conclude, such questions guarantee many decades of ethical and legal 
wrangling. We are living beings designed to forward our biological selves; when technology 
changes the landscape too quickly, we tend to become confused and resist what are often 
perceived as threats to our self-identity. Technological interference with or enhancement of 
natural processes is, simply, something that frustrates us. And while we are attempting to 
resolve the momentous issues raised, technology speeds ahead leaving a perplexed and 
somewhat paralyzed society in its wake. 
 
Nanotechnology and its applications 
Nanotechnology emerged as an important research area in the 1980s. From the beginning, 
nanotechnology has been observed to be an enabling, horizontal, and cross-sectoral 
technology (Franks, 1987). It is projected to revolutionize several industrial sectors by 
providing valuable technological innovations, but before define such research field it is 
important to address the etymology of the concept “nano”. The Greek word nanos (“dwarf”) 
is the origin of nano; meaning that a nanometer is one billionth of a meter, or roughly 75,000 
times smaller than the width of a human hair. Therefore, approximately three to six atoms can 
fit inside of a nanometer (nm), depending on the atom. 
According to The National Science Foundation nanotechnology is: “research and technology 
development at the atomic, molecular or macromolecular levels, in the length scale of 
approximately 1-100 nanometer range” (Thibodeau, 2001, pp. 1). Or, Bonsor (2002, pp. 2) 
defines it “as a branch of engineering that deals with the design and manufacture of extremely 
small electronic circuits and mechanical devices built at the molecular level of matter”. So, 
the goal of nanotechnology is to be able to manipulate materials at the atomic level in order to 
build the smallest electromechanical devices, given the physical limitations of matter and, 
which we have never been able to create and observe before (Alliance for Chemical Science 
and Technologies in Europe, 2001). In spite of being difficult to understand such concepts, 
Angelucci (2001) give us an interesting analogy, which helps to enhance the comprehension 
regarding nanotechnology. Much in the same way that Michelangelo created statues from 
blocks of marble, manufacturers today frequently create objects by first creating larger objects 
and then removing excess material by grinding, chiseling or sanding. 
When Drexler coined the word nanotechnology in the 1980s, he was discussing about 
building machines on the scale of molecules, a few nanometers wide-motors, robot arms, and 
even whole computers, far smaller than a cell (Drexler, 1986). Drexler spent the next ten 
years describing and analyzing these incredible devices, and responding to accusations of 
science fiction. Meanwhile, mundane technology was developing the ability to build simple 
structures on a molecular scale. As nanotechnology became an accepted concept, the meaning 
of the word shifted to encompass the simpler kinds of nanometer-scale technology, as 
described in another book of Drexler (1991), called the “Unbounding the Future”. In fact, the 
importance of Drexler into the research field is also recognized through the foundation of the 
Foresight Institute, which is a non-profit organization dedicated to the responsible 
development of nanotechnology (Foresight Institute, 2000). However, this theoretical 
capability was envisioned in 1959 by the renowned physicist Richard Feynman in his lecture, 
“There’s Plenty of Room at the Bottom”, concerning miniaturization down to the atomic 
scale. 
Applications of nanotechnology extend to several fields, following four generations of 
nanotechnology development (Roco, 2002; Roco, 2003). The present era, as Roco illustrates 
it, concerns passive nanostructures, materials designed to perform one task. The second phase, 
started around 2005, and introduced active nanostructures for multitasking. The third 
generation is expected to begin emerging around 2010 and will feature nanosystems with 
thousands of interacting components. After that, a few years later it will arise the first 
integrated nanosystems, similar to a mammalian cell with hierarchical systems within 
systems, are expected to be developed. 
When we argue about non-linked medical applications in nanotechnology it is possible to 
acknowledge the following dimensions: nano-computers and defect tolerant computer 
architectures (Heath et. al., 1998). In the field of microelectronics we have the following 
examples: the replacement of silicon with carbon nanotubes in a transistor (McEuen, 1998); 
miniaturization of electronic devices (Sohn, 1998); and, DNA-based computing (Seeman, 
1998). These advances have taken place with parallel advances in methodologies and 
instrumentation such as scanning tunneling microscopy (Quate, 1991). 
Concerning the analytical aim, examples of nanotechnology generations in biomedical and 
biotechnology are: targeted drug delivery, gene therapy, and nanomedicine (biomechatronic 
human prostheses for locomotion, manipulation, vision, sensing, and other functions, such as: 
artificial limbs, artificial internal organs, artificial senses, human augmentation) (Bogunia-
Kubik & Sugisaka, 2002). This field has important connection with neuroscience, to develop 
neural interfaces and sensory motor coordination systems for the integration of these bionics 
devices to human body/brain. However, given the nature of our contribution we will approach 
the major medical applications concerning nanomedicine: 
• thermotherapy; 
• photodynamic therapy; 
• chemotherapy; 
• radiotherapy. 
 
Hyperthermia therapy is based on the fact that tumour cells are more sensitive to temperature 
increase than normal tissue cells (Cavaliere et al., 1967). The most common processes are: 
photo-thermal ablation therapy using silica nanoshells (Hirsch et al., 2003); photo-thermal 
ablation therapy using carbon nanotubes for selective tumour cell destruction without harming 
normal cells in vitro (Kam et al., 2005); magnetic field-induced thermotherapy using 
magnetic nanoparticles (Jordan et al., 2001). 
Photodynamic therapy is an emerging treatment modality where a light-sensitive molecule or 
photosensitiser exposed to visible or near-infrared light induces cytotoxic effects in the 
presence of oxygen. Photodynamic therapy can be used to treat a variety of oncological, 
cardiovascular, dermatological, ophthalmic, and immunological disorders (Trauner & Hasan, 
1996), and existing two major processes: quantum dots as photosensitisers and carriers 
(Dubertret et al., 2002); and, ceramic-based nanoparticles as carriers (Yan & Kopelman, 
2003). 
Chemotherapy is another emergent treatment for cancer which has three different medical 
applications: nano-structured polymer capsules (Radt et al., 2004); dendrimers (Li et al., 
2003); and, nanocells (Semenza, 2000). Finally, radiotherapy can be characterized as an 
experimental approach to cancer treatment, as is supported by the following techniques: 
dendrimers for boron neutron capture therapy (Barth et al., 1994); carbon nanotubes for boron 
neutron capture therapy (Yinghuai et al., 2005); and, gold nanoparticles (Hainfeld et al., 
2004). 
Finally an important question arises: why is the length scale of nanotechnology so important? 
According to the Los Alamos National Laboratory (2008), there are five reasons: 
• the wavelike properties of electrons inside matter are influenced by variations on the 
nanometer scale. By patterning matter on the nanometer length scale, it is possible to 
vary fundamental properties of materials without changing their chemical 
composition; 
• the systematic organization of matter on the nanometer length scale is a key feature of 
biological systems; 
• nanoscale components have very high surface areas, making them ideal for use in 
composite materials, reacting systems, drug delivery, and energy storage; 
• the finite size of material entities, as compared to the molecular scale, determine an 
increase of the relative importance of surface tension and local electromagnetic 
effects, making nanostructured materials harder and less brittle; 
• the interaction wavelength scales of various external wave phenomena become 
comparable to the material entity size, making materials suitable for various opto-
electronic applications. 
 
The ethical dimensions of nanotechnology 
With such fearful dangers inherent in nanotechnology, we have to seriously analyze its 
potential consequences. Granted, nanotechnology may never become as powerful and prolific 
as envisioned by its evangelists, but as with any potential, near-horizon technology, we should 
go through the exercise of formulating solutions to potential ethical issues before the 
technology is irreversibly adopted by society. We must inspect the ethics of developing 
nanotechnology and create policies that will aid in its development so as to eliminate or at 
least minimize its damaging effects on society (Sweeney, Seal & Vaidyanathan, 2003). 
However, the ethical implications of nanotechnology are simultaneously unpredictable and 
predictable. 
In his novel The Nanotech Chronicles, Michael Flynn (1991) presents his view on the gradual 
development of future nanotechnology and its social implications throughout six nano-science 
fiction stories, which can provide us some interesting directions regarding such matter. 
However, we tend to ignore that the ethical perception concerning biotechnology can be a 
good starting point for the ethical implications of nanotechnology, as suggested by Weil 
(2001), or Wolfson (2003). Moreover, the principles that Richard Severson (1997) outlines in 
his book, “The Principles of Information Ethics”, to guide IT ethical decisions are also 
insufficient to this analysis. In our opinion, the ethical analysis concerning nanotechnology 
should engage the implications link between: 
• individual level; 
• professional level; 
• and, societal level. 
 
Nanotechnology as a tremendous impact on individual identity because the ethical concept of 
life revolves around nanotechnology in accordance to Venneri (2003, pp. 234): 
“nanotechnology encompasses the attributes of self-generation, reproduction, self-assembly, 
self-repair and natural adaptation”, and clearly these are all attributes we ascribe to living 
things. The other, less prodigious aspect of how the concept of life might change with 
nanotechnology regards the promises of nanomedicine. Nanotechnology may be able to repair 
or reproduce tissue, diagnose disease (e.g. cancer) at a very early stage, dispense drugs at the 
cellular level, and even reverse diseases. Therefore, our concept of the human life span may 
be revolutionized as a result; people may live longer by techniques considered by many as 
artificial. Some will wonder if nanotechnologists are “playing God” by tinkering so directly 
with nature. Others will wonder to what extent humanity and nanomachinery will blend; if we 
are downloaded into our technology, what are the chances that we will thereafter be ourselves 
or even human (Weckert, 2001)? 
Plus, future nanotechnology-enabled, implanted or swallowed diagnostic tools will make 
possible the collection of an enormous amount of individual cellular/subcellular level 
surveillance data of the human body, which is remotely transmitted to a medical database 
server to be analyzed and monitored by a diagnostic software. If and when such technologies 
become possible, a crucial ethical question arises: can the health information infrastructure 
handle, collect, process, and analyze real-time on-going health data? Moreover, ensuring 
privacy and confidentiality in such a system would be of utmost importance; a system without 
adequate safeguards presents serious ethical problems. 
From the above, it is clear that an in-depth ethical analysis must fulfil the following 
requirements in order to achieve human dignity (United Nations Educational, Scientific and 
Cultural Organization, 2006): 
• non-instrumentalisation- the ethical requirement of not using individuals merely as a 
means but always as an end of their own; 
• privacy- the ethical principle of not invading a person’s right to privacy; 
• non-discrimination- people deserve equal treatment, unless there are reasons that 
justify difference in treatment. It is a widely accepted principle and in this context it 
primarily relates to the distribution of health care resources; 
• informed consent- the ethical principle that patients are not exposed to treatment or 
research without their free and informed consent; 
• equity- the ethical principle that everybody should have fair access to the benefits 
under consideration; 
• the precautionary principle- this principle entails the moral duty of continuous risk 
assessment with regard to the not fully foreseeable impact of new technologies as in 
the case of ICT implants in the human body. 
 
At a professional level nanotechnology can raise the following issues to its practitioners 
(Flynn, 1991): 
• the dimensions of intended and unintended social consequences of technological 
innovation, including attempts to fix unintended consequences by technological 
implementation, and cultural conservatism; 
• understand the limits of social foresight and of planning technology-induced social 
changes; 
• the different kinds of interests and values that professionals are confronted and the 
need for responsible decisions; 
• risk analysis and the social relativity of risk perception; 
• standard excuses from moral responsibility. 
 
Finally, at a societal level we may refer that nanotechnology embraces potential dangerous for 
the environment. In 2002, researchers reported to the Environmental Protection Agency 
(EPA) that nanoparticles have appeared in the livers of research animals and that there is a 
potential for nanoparticles to piggyback on bacteria and enter the food chain. There is no 
regulatory body that is tracking nanomaterials, so we could be releasing an undetectable toxin 
into the biosphere (Rupley, 2002). However, the ethical dilemmas are far more complex 
rather than environmental issues. 
An essential feature that sets nanostructures apart from other artefacts is size. They are from 1 
to 100 nanometers, from one- to 100-billionths of a meter, significantly less than the 50,000 
nanometers of a human hair. Obviously, they cannot be perceived by the naked eye (Ratner, 
2003, pp. 6), and can thus be produced and deployed without ever being observed by any 
human being. The kinds of ethical issues this unobservability creates can be illustrated by 
noting three problems: privacy; intrusion; disclosure and appropriation. These problems are 
external to nanotechnology. They arise through what are predictably the ordinary uses made 
of nanostructures or, as a consequence of being nanostructures at all. 
Concerning privacy, we could simply add nano-sensing devices to the paint or a composition 
floor to turn a ‘safe’ room into a recording and transmitting studio. Alternatively, such 
devices could be put into our bodies without knowing. The average citizen would be at the 
complete mercy of anyone familiar with nano-sensing. Their detection would require what we 
can presume to be special highly sophisticated equipment (Robison, 1994). 
We are also helpless to preclude disclosure, the second privacy tort. The standard sort of 
example is someone’s passing on a secret. The secret is disclosed. We all keep some 
information to ourselves. This is, among other things, one way of distinguishing between 
friends, acquaintances and strangers. We tell friends things about ourselves that would be 
inappropriate to tell our acquaintances (although that would be one way of beginning to turn 
an acquaintance into a friend). Telling such things to strangers would mark us as addled, if not 
crazy. Control over information about our personal lives allows us to keep, among other 
things, control over who we are: publicly, and privately. Nanosensors would allow a stranger 
to know everything about us that we would want to control, from private conversations with 
one’s spouse or lover to intimate details about one’s body temperature and state of health. A 
stranger could well know far more about us than we can know about ourselves (Robinson, 
2004). That someone knows as much or more about us as we do concerns the last relevant 
privacy tort, namely appropriation. That occurs when someone takes another’s identity. Such 
theft will become as easier as information about us is relayed to a stranger who will pick up 
all those conversations we think are private, and use that information to appropriate our 
identity (Robinson, 2004). In each case- intrusion, disclosure and appropriation- our privacy 
is invaded, and of course such invasion can obviously also be harmful. 
 
Focus 
Bionanotechnology and its applications 
After debating biotechnology and nanotechnology, how can we define bionanotechnology as 
a research field? Presently, a lack of consensus concerning such concept is a reality. However, 
to take advantage of the enthusiasm of funding agencies, a number of old (and important) 
areas, such as colloid science, molecular biology, and implantable materials surface science, 
have been relabeled nanotechnology. In fact, all of these fields coupled with biological 
systems, should be included in bionanotechnology. Therefore, the idea of bionanotechnology 
embraces engineering interfaces between molecules or materials and biological systems, 
which clearly involve a wider, or a blurred definition. 
Even acknowledging the following definitions the quandary holds: “bionanotechnology 
claims that it is a multi-disciplinary area that sits at the interface between engineering and the 
biological and physical sciences” (Biotechnology and Biological Sciences Research Council, 
2007, pp. 1); while the Organization for Economic Co-operation and Development defines it 
as “an area that covers the interface between physics, biology, chemistry and the engineering 
sciences” (Organization for Economic Co-operation and Development, 2005, pp. 4); or, 
“bionanotechnology represents the convergence of nanotechnology and biotechnology, 
yielding materials and products that use biological molecules in their construction or are 
designed to affect biological systems”(North Carolina Biotechnology Center, 2007, pp. 3). 
Referring the non-linked applications to e-health it is possible to point out the following ones: 
engineering biomolecules for non-biological use, such as DNA-based computer circuits using 
nanotechnology tools. As linked applications to e-health literature acknowledges the 
following ones: nanomaterials with biological systems for outcomes such as targeted drug 
therapies, nanobiological materials for human body enhancement. 
However, despite the political rhetoric and normative discourses that claim the prospective of 
such technology, due to immeasurable institutional inflexibility (insecure career paths, unfair 
evaluation, need of longer training), the truth is that the conventional wisdom concerning its 
benefits is not supported by systematic evidence and remains poorly understood (Schild & 
Sorlin, 2005). Although since the 1990s there has been an outstanding output of new 
empirical studies to add to the more plentiful conceptual and normative approaches adopted in 
the past, there is a worrying lack of consensus even about how to measure cross-disciplinarity 
(Bordons, Morillo & Gómes, 2004). Another crucial aspect that still needs to be evaluated is 
the costs and risks of failure regarding its ethical and moral dilemmas. 
 
Technological example 
A practical application of bionano materials will be the possibility to replace cells or 
molecules when a serious traumatic injury affects your body. In the Department of Chemistry 
at Johns Hopkins University researchers have found through the observation of Alzheimer’s 
patient’s tissue, that is composed by plaques made from very small fibbers (Institute for 
Nanobiotechnology, 2008). These fibbers are very, very long and narrow; however, they 
perfectly match when combined or reproduced. 
At this point, we need to approach the concept of severe traumatic injury in a medical sense: 
body or emotional injury resulting from physical or mental wound or shock. A traumatic 
injury is caused by something outside the person's body as opposed to a sickness or a disease. 
An example would be injury to a hand that is smashed in a machine, a car accident that lead to 
a severe damage into your spinal cord, or still a nervous breakdown caused by stress on the 
job (Medical Dictionary, 2003). When a traumatic injury occur communication between nerve 
cells is lost, because the flux of electrical signs is interrupted. So, these bionano materials 
with the ability to reproduce themselves will allow re-establishing communication between 
such cells, because they are a combination of semiconductor (electronics carbon based) and 
organic (biological tissue) parts. 
However to establish a bound between such technology and telemedicine we need to 
approach the proceeding method between the medical application and doctor’s medical 
guidance. We can distinguish two levels of analysis: 
• the communicational act between patient and doctor; 
• and, the new technological capabilities that these applications will provide to medical 
staff. 
 
The communicational process embraces two different perspectives to this kind of treatment: 
remote application if only a traumatic injury happens, or the introduction of such treatment as 
a “vaccine” into the human body allowing immediate treatment after such injury. Despite the 
possible choice, if the bionanorobots intervene due to a traumatic injury communication is 
immediately established, allowing that medical staff monitor the process and compare the 
data collected with the existing one. Furthermore, the technological capabilities that are 
bounded to such treatments are: Virtual Reality and telematic. Virtual Reality not only 
provides immersive visualization, but also gives an added functionality of navigation and 
interactive manipulation of molecular graphical objects. Plus, it also provides the opportunity 
to medical staff to experience the perception and interaction with our body, given the 3D 
image environment. Telematic will make possible to remote the system with feedback 
through sensors, which engages different reactions depending on the type of material the 
operator is dealing with, and imitation tools at the workstation corresponding to the actual 
tools of nanorobots. 
Concluding, it is clear that such medical applications embrace a wide range of ethical issues, 
which will be under debate into the following section. 
 
The ethical dimensions of bionanotechnology 
Given the previous sections human body enhancement is the main feature concerning 
bionanotechnology medical applications. If we are incorporating computer chips into our 
body, it could be understood as a violation of “natural” boundaries? Should we develop 
devices that interact directly with the brain, or that exert internal or external controls over 
bodily and mental functions? What effect would a neurotransplant have on humans, and in 
what extent will we be responsible for our actions? What is the relationship between one’s 
identity and one’s body? At this point, it is unfeasible to know the outcome of such answers, 
but we should discuss the concept of enhancement, as well as its ethics. 
Enhancement is in its essence improving or adds new capacities to the human body. In spite 
of its concise definition, it is defined as an ambiguous concept which can mean better and 
more, but also something that most people may think to be less desirable and that should be 
avoided. The negative evaluation of enhancement appears in the first half of last century due 
to the appearance of eugenics. However, the difference seems to rely on the “old” eugenics 
versus the “new” eugenics on free choice and autonomy (liberal eugenics) (Agar 2004). 
Nonetheless, the basic idea is the same, namely the wielding out of undesirable physical and 
psychological traits. 
In order to get a better understanding of the moral value of enhancement, we need to discuss 
the concept of therapy. Therapy concerning enhancement technology is often seen as 
something “good”, while enhancement is frequently something negative. Such answer is 
related to the medical paradigm, and even if drawing a sharp line between therapy and 
enhancement was possible, we would still face the problem of knowing what counts as an 
enhancement. In order to diminish the lack of uncertainty, we plead three arguments that 
describe an enhancement in spite of the potential critics that possibly will arise due to the 
individual notion of human limits or limitations (see for example, Nordmann, 2007): 
• certainity- the pyshical, psychological and cognitive characteristics of the human body 
are enhanced; 
• consistency- the outcome of such “biological manipulation” is similar to an 
“environmental manipulation”. There is no relevant moral difference between them; 
• similarity- if we accept treatment and disease prevention, we should accept 
enhancement. The goodness of health is what drives a moral obligation to treat or 
prevent disease. 
 
To debate the ethics of enhancement we will focus our attention on the following authors: 
• Kass and Fukayama- do not endanger human nature; 
• Habermas- on enhancement and moral status; 
• Sandel- enhancement as a threat to central human goods. 
 
Despite countless discrepancies in their analysis, Leon Kass and Francis Fukayama both warn 
that biomedical interventions aimed at enhancement might destroy human nature (Fukuyama, 
2002; Kass, 2001). Both could be interpreted as providing an anti-enhancement, because they 
assume that the destruction of human nature would be so terrible that excludes, or at least 
clearly outweighs any reasons in favor of doing that which threatens such destruction. In our 
opinion such claim tends to fail because for example Blake (2007) pleads the idea that the 
future does not humans which contradicts the criticism concerning enhancement through 
biomedical applications. 
Moreover, Habermas (2003) consider that this sort of enhancement violates the principle of 
equity dictating people as free beings. He also apparently, believes that something violating 
this fundamental principle maybe a conclusive reason for avoiding it, not merely as a reason 
against it, but against reasons in favour of it. So, Habermas (2003) argues that any 
consideration in favour of genetic engineering enhancements should be irrelevant. 
Finally, Sandel’s disagreement against enhancement is that the effort to enhance human 
beings both expresses morally flawed attitudes and undermines virtuous ones. Sandel claims 
that those who pursue enhancement act as a boundless craving for “mastery” and thereby 
contribute to erosion, in themselves and others, of the sense of “the giftedness.” The sense of 
“giftedness,” according to Sandel, includes an acceptance of the limitations of human powers 
and “openness” to what we cannot control and, it is a precondition for having proper humility 
and perhaps other virtues as well. So, Sandel consider that the sense of “giftedness” is or is 
necessary for fundamental human goods and that biomedical enhancement endangers it 
(Sandel, 2002). However, it seems to us that the argument introduced by Sandel (2002) seems 
to not fulfil a conclusive reasoning for forgoing biomedical enhancements. In fact, the main 
assumptions of Sandel can be outlined as follows: 
• the sense of the giftedness is a central human good; 
• the drive for mastery is incompatible with the sense of giftedness.; 
• the employment of biomedical enhancements is an instance of the drive for mastery; 
• therefore, the employment of biomedical enhancements is incompatible with the sense 
of giftedness. 
 
In conclusion, it is clear that such discussion is an ongoing dialectic process that entails into a 
personal view about the concept of human being and its limits or boundaries. 
 
Future Trends 
To promote an insight perspective considering future trends of these domains we 
acknowledge the need for a “holistic human project” that could bring together the best 
research clinicians, biomedical engineers, biomedical scientists, nanotechnologists, and 
others, because the great convergence that is taking place today should not be mistaken with 
the mundane growth of interdisciplinary or multidisciplinary fields. The aim of such project 
should be a continuous discussion concerning life-shortening diseases and conditions versus 
current progress or problems in their treatment or eradication, because as Miller stated in 
1969, such circumstances would be possible to achieve through the “continuously 
monitorization by modern instrumentation of the physiological function” (pp. 443-444). 
However, public trust in science cannot be achieved without an open and transparent 
communication about the potential or perceived risks associated with the technology, because 
as Jesús Mosterín (2002) emphasizes: technology itself is ethically neutral, and its impact 
depends on how it is used. In spite of such claim, we also agree with the critique claimed by 
Horner (2007), concerning the ability to forecast ethics existence based on the argument of 
generational choice. The truth is that ethical issues emerge if the development of new 
technologies or their prospective products conflicts with a society’s ethical standards. While 
governments and institutions’ cannot control the ethical standards of their society, they are 
required to minimize the conflict, using four ways: 
• enacting regulations to protect people from risks; 
• supporting research to provide necessary knowledge concerning the stakeholders 
decision-making; 
• educating the public on the various pros and cons of the technology in question to 
enable educated public technology assessment; 
• and involving citizens in technology governance to increase the conflicts. 
 
Given the complex and global nature of our focus, the truth is that concerning regulations the 
United Nations should convene an international conference with a view to the creation of a 
permanent international multi-stakeholder body to review, monitor and regulate 
developments. There is as much reason to create such a body as there was to create the 
International Atomic Energy Agency with its monitoring powers. 
In accordance to Varvasovszky & Brugha (2000), a stakeholder analysis is an approach, a tool 
or set of tools to generate knowledge about players so as, to understand their behaviour, 
intentions, interrelations and interests. For assessing the influence and resources they bring to 
bear on decision-making or implementation processes. A stakeholder, in this context, is any 
organization, individual, or entity that is involved with or, can stand to gain or lose in a 
certain venture. However, throughout literature it is possible to acknowledge scarcity 
concerning the identification of the stakeholders, because generally such analysis is named by 
societal debate. Plus, none actually demonstrate a concrete methodology for performing a 
stakeholder analysis on such research fields, and the four key steps that characterize 
traditional stakeholder analysis: 
• identify the stakeholders involved; 
• identify the stakeholders’ views on, and stake in; 
• assess stakeholder interest in or influence over the issue; 
• and, create strategies to deal with the problems a multitude of stakeholders with 
different stakes. 
 
Do not respond in an effective way to the quoted challenges. Moreover, one of the purposes 
of educating the public is to allow that citizens feel more comfortable concerning the 
development of new technologies. The main issue is to provide accurate and balanced 
information which citizens think they needed in order to, decide whether technologies 
constitute or not a significant risk. However, an underlying issue may be a lack of knowledge 
about the processes of conducting scientific research and developing new technologies, and a 
naive understanding of how risk is assessed and regulations constructed. All these issues must 
be clarified, framed and explained to citizens, in order to reduce their frustration, and even 
change their opinion). 
Finally, involving citizens in technology governance will allow a continuous dialectic 
approach to moral, social, legal and ethical behaviours, as for example concerning the 
following issues (Wickramasinghe, Choudhary & Geisler, 2007): 
• will we be able to differentiate such technologies?; 
• where will we stop?; 
• will genetic modifications that increase sustainability breech our current definition of 
being “human”?. 
 
So, such governance will allow conflicts ameliorating. 
 
Conclusion 
Throughout this contribution we have acknowledged the arguments that allow us to reveal the 
answers to the sub research questions. Plus, we were able to respond to the primary research 
question: how can we define bionanotechnology as a research field? However, the sub-
research questions that derive from such field remain answered. 
In our opinion, bionanotechnology encompasses not only the ethical dilemmas that prevail in 
each, biotechnology and nanotechnology research fields, but enhanced such dilemmas. The 
main reason for our argument is simple, and probably debatable; however, we introduce two 
valid assumptions in order to justify it: 
• bionanotechnology as a research field is still an unknown variable, as well as it is 
boundaries. In fact, even the scientific community disagree about the concept itself 
(see bionanotechnology and its applications); 
• the ethical and moral dilemmas engaged by biotechnology are still under debate, and 
may be considered blurred or fuzzy. Therefore, the ethical and moral dilemmas of 
bionanotechnology can be classified as even more blurry or fuzzy, which is illustrated 
by the absence/reduced of literature regarding such matter; 
 
In conclusion, because bionanotechnology is still in its childish phase this paper “draw” a 
broad picture of social and philosophical claims on the developing research field/technology, 
and of the array of ethical dilemmas. Plus, it is proved that there are already sufficient 
questions to deserve in-depth studies. Among the most important applications, particularly in 
the context of medicine, are human enhancement, human-machine interfaces, information and 
complexity in relation to nanodiagnostics, unintended consequences of targeted therapeutics, 
diversion to other fields outside medicine, and the social and ethical priorities towards which 
these technologies should be steered. 
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Key Terms 
Bionanotechnology- multidisciplinary research field that represents a convergence between 
engineering, biological sciences, physical sciences and ICT. 
 
Biotechnology- the use of organisms or their products for commercial purposes. 
 
E-health- the use of modern ICT to meet needs of citizens, patients, healthcare professionals, 
healthcare providers, as well as policy makers. 
 
Ethical dilemma- is a circumstance that often involves an apparent conflict between moral 
imperatives, in which to obey one would result in transgressing another. 
 
Health- a combination of the absence of illness, the ability to cope with everyday activities, 
physical fitness and high quality of life. 
 
Healthcare- prevention, treatment and management of illness through the services offered by 
the medical, nursing and allied health professions. 
 
ICT- a range of technologies for gathering, storing, retrieving, processing, analysing, 
transmitting and receiving information. 
 
Moral dilemma- when an agent as moral reasons to do each of two actions, but doing both 
actions is not possible. 
 
Nanotechnology- creation of functional materials, devices and systems through control of 
matter on the nanometer length scale, as well as, their exploitation. 
 
Telemedicine- the delivery of healthcare and information across distance through the use of 
ICT. 
